Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

Bacteremia Clinical Trial

— Bacteremia  

Official title:

A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01191840
• Other study ID #: Pro00025497
• Secondary ID: DMID Protocol Nu
• Status: Completed
• Phase: Phase 2
• First received: August 28, 2010
• Last updated: December 12, 2017
• Start date: February 2011
• Est. completion date: March 4, 2017

Study information

• Verified date: December 2017
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to accurately determine the length of appropriate drug treatment for staphylococcal blood stream infection. The study seeks to address important information about the management of staphylococcal blood stream infections.

Description:

To demonstrate that the clinical efficacy of algorithm-based therapy of patients with staphylococcal blood stream infection is noninferior to current standard of care.

PP (per protocol) population: randomized patients EXCLUDING those that: Received a PENS antibiotic -Did not undergo removal of intravascular catheter suspected to be infected. Note that patients with simple CoNS bacteremia may retain the catheter; all other patients should have their catheter(s) removed. -Had blood stream infection with a vancomycin-resistant staphylococcus; or a staphylococcus resistant to protocol-identified alternative drugs if these were used -Discontinued study medication prematurely for reasons other than clinical failure -Did not undergo final TOC assessment -Did not comply with all Patient Inclusion Criteria -Violated any Patient Exclusion Criteria

• Died within 3 days of randomization

• Were classified as non-evaluable

PPE Population: Patients from the PP population who did not have complicated staphylococcal infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 509
• Est. completion date: March 4, 2017
• Est. primary completion date: March 4, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provide signed and dated informed consent. The patient's legally authorized representative (LAR) can provide a signed informed consent for the patient if allowed by local Institutional Review Board/Ethics Committee (IRB/EC) policy.

2. Is = 18 yrs of age.

3. If the subject has an intravenous catheter in place then the subject and his/her primary health care provider must agree to have the catheter removed within 5 days of the initial blood culture draw with the exception of those subjects who meet criteria for simple CoNS bacteremia as defined in Table 1. The catheter may be retained in those subjects with simple CoNS bacteremia.

4. Has blood stream infection defined as at least one blood culture positive for S. aureus or CoNS. In most cases, vancomycin(or other study drug alternative) will have been started prior to randomization. Enrollment windows depend on speciation and clinical classification as follows:

1. identification of CoNS and classification as simple per Table 1-must be randomized within 3 calendar days of the start of treatment effective for the baseline infecting pathogen

2. identification of CoNS and classification as uncomplicated per Table 1 must be randomized within 4 calendar days of the start of treatment effective for the baseline infecting pathogen

3. identification of S. aureus - must be randomized within 12 calendar days of the start of treatment effective for the baseline infecting pathogen

5. This criterion has been removed

6. Women of child bearing potential must have a negative urine and/or serum pregnancy test.

7. All patients of reproductive potential must be abstinent or agree to use double-barrier contraception while receiving study (algorithm based or Standard of Care) therapy.

Exclusion Criteria:

1. Has known or suspected new complicated staphylococcal infection at the time of enrollment.

2. Weigh = 200 kg.

3. Has non-removable intravascular foreign material at the time a positive blood culture was drawn (e.g., intracardiac pacemaker or cardioverter/defibrillator wires, hemodialysis access grafts, cardiac prosthetic valve, valvular support ring). Exception: coronary stents, inferior vena cava (IVC) filters in place > 6 weeks, patients with pacemakers whose baseline infecting pathogen is a CoNS, vascular stents in place for > 6 weeks, non-hemodialysis grafts in place >90 days and hemodialysis grafts not used within past 12 months and not previously infected are eligible for randomization. Arthroplasties and other extravascular devices, e.g. synthetic hernia repair mesh, and non-arthroplasty orthopedic prostheses including pins or plates, are acceptable as long as there are no signs or symptoms of foreign material-related infection at the time of randomization.

4. This criterion has been removed

5. Has a moribund clinical condition such that there is a high likelihood of death or cardiac surgery during the next three days.

6. Has shock or hypotension (supine systolic blood pressure < 80 mmHg) or oliguria (urine output < 20 mL/h) unresponsive to fluids or pressors within four hours.

7. Has received an investigational antibacterial agent with anti-staphylococcal activity within 30 days prior to randomization.

8. Has a documented history of significant allergy or intolerance to all protocol-approved antibiotics anticipated to be effective for their infection.

9. Has an infecting pathogen with confirmed reduced susceptibility to vancomycin (Minimum Inhibitory Concentrations (MIC) > 2 µg/mL) if known. Note: If reduced susceptibility to vancomycin is discovered after enrollment, the patient will be treated with daptomycin (if pathogen is susceptible). Patient will remain in study as appropriate and be evaluated in the Intent to Treat (ITT) analysis, but will be excluded from Protocol Population (PP) analyses.

10. For S. Aureus patients, is severely neutropenic (absolute neutrophil count < 0.100x103/mm3) or is anticipated to develop severe neutropenia (absolute neutrophil count < 0.100x103/ mm3) during the study treatment period due to prior or planned chemotherapy. CoNS patients with neutropenia are eligible to be enrolled.

11. This criterion has been removed

12. Has previously known Human Immunodeficiency Virus (HIV) infection with a nadir CD4+ count of <100 cells/mm3 within the past 12 months

13. Is considered unlikely to comply with study procedures or to return for scheduled post-treatment evaluations.

14. Is pregnant or trying to get pregnant, nursing, or lactating.

15. Has known or suspected septic arthritis, osteomyelitis, pneumonia or other metastatic focus of infection. CoNS patients with pneumonia and not being treated or anticipated to start treatment with antibiotics effective for the baseline infecting pathogen can be included

16. Has polymicrobial blood stream infection including at least one non-staphylococcal species, except AFTER consultation with the Clinical Medical Monitor at DCRI. Note that it is possible that a subject may not have a known polymicrobial bloodstream infection at the time of randomization, but additional pathogen(s) can subsequently be isolated from the initial blood culture. These patients will be eligible to remain in the trial. Please also note that patients with S. aureus plus CoNS will follow the treatment pathway for S. aureus.

17. This criterion has been removed.

18. Is hemodialysis dependent or has end stage renal disease (Creatinine Clearance (CrCl) < 30 cc/min).

19. Developed Staphylococcus aureus blood stream infection within 72 hours of percutaneous coronary revascularization

20. Received of any of the following antibiotics for 7 or more of the 10 calendar days immediately preceding the calendar day that the initial positive blood culture was drawn:

1. If methicillin susceptibility of the isolate is unknown at the time of enrollment: vancomycin; daptomycin; telavancin; tigecycline; linezolid (in either oral or IV administration); quinupristin/dalfopristin; piperacillin/tazobactam; penicillin; nafcillin; oxacillin; cloxacillin; cefazolin, ceftriaxone, ceftaroline, dalbavancin, oritavancin, tedizolid, and levofloxacin or equivalent fluoroquinolone (in either oral or IV administration) Note: ciprofloxacin is not an exclusion criteria.

2. If the staphylococcal isolate is known to be methicillin resistant: vancomycin; daptomycin; telavancin; tigecycline; linezolid (in either oral or IV administration), quinupristin/dalfopristin, dalbavancin, oritavancin, tedizolid, and ceftaroline.

Note: patients who have developed bacteremia after at least 7 days of prophylaxis with oral antibiotics have by definition failed prophylaxis and the oral antibiotic can be deemed non-effective for the index bacteremia. Oral antibiotics that have failed as prophylaxis in this manner will not be considered exclusionary or count towards the number of antibiotic days but must be stopped upon randomization

21. Has previously participated in this study.

Related Conditions & MeSH terms

• Bacteremia

Intervention

Drug:
• Vancomycin
Duration
• Vancomycin
Duration

Locations

Country	Name	City	State
Spain	Fundacio Clinic Privada per a la Recera	Barcelona
United States	University of Alabama, Birmingham	Birmingham	Alabama
United States	Albert Einstein College of Medicine	Bronx	New York
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Carolina Medical Center	Charlotte	North Carolina
United States	University of Colorado	Denver	Colorado
United States	Henry Ford Hospital	Detroit	Michigan
United States	Duke University Medical Center	Durham	North Carolina
United States	Brody School of Medicine at ECU	Greenville	North Carolina
United States	Greenville Hospital System	Greenville	South Carolina
United States	UT MD Anderson Cancer Center	Houston	Texas
United States	David Geffen School of Medicine UCLA	Los Angeles	California
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	William Beaumont Hospital	Royal Oak	Michigan
United States	University of Mass	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	National Institutes of Health (NIH)

Countries where clinical trial is conducted

United States,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cure Rate	To compare the cure rate at Test of Cure evaluation, between the proposed treatment algorithm and the standard of care therapy.	Test of cure 2 (up to approximately 42 days)
Primary	Number of Participants With Serious Adverse Events	Number of Participants that reported a Serious Adverse Event	Test of cure 2 (up to approximately 42 days)
Primary	Number of Participants With Adverse Events Leading to Study Drug Withdrawal	Number of Participants with an Adverse Event leading to study drug withdrawal	Test of cure 2 (up to approximately 42 days)
Primary	Number of Participants That Changed From Vancomycin to Another Study Antibiotic Due to an Adverse Event	Patient changes from vancomycin or a protocol-approved study antibiotic to another protocol-approved study antibiotic due to AE associated with study drug	Test of cure 2 (up to approximately 42 days)
Secondary	Antibiotic Days by Treatment Group	This will be analyzed by evaluating the difference in antibiotic days by treatment group and calculating 95% confidence intervals around the difference in antibiotic days among study patients randomized to algorithm-based treatment vs. among study patients randomized to standard treatment.	Test of cure 2 (up to approximately 42 days)